贝瑞基因股价跌5.33%，永赢基金旗下1只基金位居十大流通股东，持有152.68万股浮亏损失109.93万元

Group 1 - Berry Genomics experienced a decline of 5.33% on January 16, with a stock price of 12.78 CNY per share, a trading volume of 288 million CNY, a turnover rate of 6.64%, and a total market capitalization of 4.518 billion CNY [1] - The company, established on April 14, 1997, and listed on April 22, 1997, is based in Beijing and specializes in high-throughput sequencing technology for genetic testing, along with the sale of equipment and reagents [1] - The revenue composition of Berry Genomics includes reagent sales at 45.74%, medical testing services at 31.24%, basic research services at 18.33%, equipment sales at 3.48%, and other sources at 1.20% [1] Group 2 - The top circulating shareholder data indicates that a fund under Yongying Fund ranks among the top shareholders of Berry Genomics, with the Medical Device ETF (159883) newly entering the top ten shareholders in the third quarter, holding 1.5268 million shares, which accounts for 0.46% of circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, yielding 11.25% this year, ranking 708 out of 5531 in its category, and achieving a 17.13% return over the past year, ranking 3570 out of 4215 [2] - The fund has experienced a cumulative loss of approximately 45.72% since its inception [2]